11 papers · updated 2026-09-26 · Hand & Upper Extremity · All topics
The newest papers on Dupuytren disease from the orthopaedic journals The Reduction reads, newest first, each with a one-line summary. The list is drawn from the digest’s archive and refreshed every week.
Get new Hand & Upper Extremity papers by email, free: subscribe to The Reduction, focused on your interests, on the days you pick.
A photograph-based virtual pathway for patients with Dupuytren's disease.
A photograph-based virtual triage pathway for Dupuytren's disease cut unnecessary clinic visits by 46% while maintaining high patient satisfaction, supporting remote assessment models for hand referrals.
Treatment Injuries in Dupuytren Contracture: A Population-Based Study of Filed Compensation Claims.
Finnish registry data show a low rate (4 per 1,000 operations) of compensation claims after Dupuytren contracture treatment, with nearly 30% deemed avoidable, mostly nerve/tendon injuries and infections.
Screening for amyloidosis in trigger finger release and Dupuytren's fasciectomy.
Screening surgical specimens found amyloid deposits in 5% of trigger finger releases (mostly transthyretin type) but none confirmed in Dupuytren fasciectomy tissue, suggesting trigger finger release may aid early amyloidosis detection while fasciectomy tissue does not.
Over 21 years of Medicare data, collagenase injection has increasingly displaced open surgery for Dupuytren contracture alongside rising public interest, even as inflation-adjusted physician reimbursement fell 42% across all treatments.
Trends in Treatment and Reimbursement of Dupuytren Disease.
Over 20 years, minimally invasive Dupuytren treatments increased while fasciectomy declined, but inflation-adjusted reimbursement dropped 38%, signaling growing financial pressure on providers.
Dupuytren's disease: a state-of-the-art review.
This state-of-the-art review covers Dupuytren's disease epidemiology, risk factors, pathogenesis, and current non-surgical and surgical treatment options.
After Dupuytren treatment in one digit, over 40% of patients need further intervention within 5 years, so counsel on risks tied to age, smoking, and untreated digits.
Pharmacotherapies in Dupuytren Disease: Current and Novel Strategies.
This review surveys current and emerging pharmacotherapies—beyond the FDA-approved collagenase—for Dupuytren disease, noting most lack strong long-term clinical data.
Advanced Dupuytren Contracture: Approach to Management.
This article reviews management strategies for advanced or recurrent Dupuytren contracture, including skin grafting, external fixation, radiation, and adjuvant therapies to reduce recurrence.
Treatments for early-stage Dupuytren's disease: an evidence-based approach.
Review argues that targeting TNF with intranodular adalimumab injections, guided by molecular understanding of early Dupuytren's nodules, offers an evidence-based option before flexion contractures develop.
Dupuytren Contractures: An Update of Recent Literature.
This review updates recent literature on Dupuytren contracture pathophysiology and treatment, highlighting growing use of collagenase injection alongside needle aponeurotomy and fasciectomy.
Injectable Collagenase Clostridium Histolyticum: A New Nonsurgical Treatment for Dupuytren's Disease
RCT showed injectable collagenase clostridium histolyticum significantly reduced Dupuytren's contractures versus placebo, supporting it as an effective, well-tolerated nonsurgical alternative to fasciectomy.
Dupuytren's disease, carpal tunnel syndrome, trigger finger, and diabetes mellitus
Reviews the well-established link between diabetes and hand conditions like Dupuytren's, carpal tunnel syndrome, and trigger finger.
Home · All topics · Archive · Subscribe · FAQ
© 2026 The Reduction